Hepatitis B and Delta in Peru: Current Status and Control

Descripción del Articulo

Hepatitis B virus is a highly infectious DNA virus, and the chronic carrier status may lead to cirrhosis and liver cancer. These conditions may supervene in a short time period if there is coexistence of both hepatitis B and D viruses, as it usually occurs in Peru. Our country has an intermediate en...

Descripción completa

Detalles Bibliográficos
Autores: Cabezas Sánchez, Cabezas Sánchez, Cabezas Sánchez, César
Formato: artículo
Fecha de Publicación:2018
Institución:Colegio Médico del Perú
Repositorio:Acta Médica Peruana
Lenguaje:español
OAI Identifier:oai:amp.cmp.org.pe:article/2631
Enlace del recurso:https://amp.cmp.org.pe/index.php/AMP/article/view/2631
Nivel de acceso:acceso abierto
Materia:hepatitis B/epidemiología
transmisión
prevención & control
Hepatitis D/epidemiología
Perú
hepatitis B / epidemiology
transmission
prevention & control
hepatitis D / epidemiology
Peru
id REVCMP_3d7e26c3373c2b03a545ea29dedb45d6
oai_identifier_str oai:amp.cmp.org.pe:article/2631
network_acronym_str REVCMP
network_name_str Acta Médica Peruana
repository_id_str .
spelling Hepatitis B and Delta in Peru: Current Status and ControlSituación y control de la hepatitis B y Delta en el PerúCabezas Sánchez, Cabezas SánchezCabezas Sánchez, Césarhepatitis B/epidemiologíatransmisiónprevención & controlHepatitis D/epidemiologíaPerúhepatitis B / epidemiologytransmissionprevention & controlhepatitis D / epidemiologyPeruHepatitis B virus is a highly infectious DNA virus, and the chronic carrier status may lead to cirrhosis and liver cancer. These conditions may supervene in a short time period if there is coexistence of both hepatitis B and D viruses, as it usually occurs in Peru. Our country has an intermediate endemicity, although there are areas with high, medium and low endemicity; however, migration is spreading these infections. It is important to point out that there is horizontal transmission in children from endemic areas and a low level of vertical transmission, which is an advantage in order to achieve early protection using the hepatitis B vaccine. This vaccine HBV is efficacious and safe, and vaccination is still one of the most cost-effective interventions. Pilot hepatitis B vaccination programs have been implemented in Peru, achieving a significant impact on the infection rates; so it is advisable to expand the target population, particularly teenagers and other risk groups, so that the time period to eliminate hepatitis B infection may be shortened, as well as its chronic sequels. There have been some advances in prevention, but we still have to take care of chronic carriers. Knowing that there are therapy strategies available for subjects positive and negative for HBeAg, it is advisable to propose therapy programs and to assess all interventions performed. These are the topics included in this review.El virus de la hepatitis B es un virus DNA altamente infeccioso cuyo estado de portador crónico conlleva a la cirrosis y el cáncer de hígado y esto se da en plazos mas cortos si está asociado al virus D como ocurre en el Perú. Nuestro país tiene en promedio una endemicidad intermedia, aunque hay áreas de alta, mediada y baja endemicidad; sin embargo la migración de personas entre estas áreas, está dispersando la infección. Debe destacarse en el pais la transmisión horizontal en niños de áreas endémicas y la baja transmisión vertical, lo que es una ventaja para proteger tempranamente con la vacuna. La vacuna disponible contra HBV es eficaz y segura, y siendo la vacunación una de las intervenciones más costo efectivas, se han desarrollado programas de vacunación piloto en el país, con un significativo impacto sobre la tasa de infección; por lo que amerita ampliar la población objetivo a inmunizar, como son los adolescentes y jóvenes y grupos de riesgo de manera que se acorten los periodos para eliminar la infección por HBV y por tanto sus secuelas crónicas. Hay avances en la prevención, pero aun queda que hacer con los portadores crónicos. Habiendo perspectivas terapéuticas tanto para los HBeAg positivos y HBeAg negativos, será pertinente plantear programas de tratamiento y de otro lado evaluar todas las intervenciones efectuadas. Estos son los temas que se incluyen en esta revisión.Colegio Médico del Perú2018-06-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/2631ACTA MEDICA PERUANA; Vol. 25 No. 2 (2008); 96-112ACTA MEDICA PERUANA; Vol. 25 Núm. 2 (2008); 96-1121728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/2631/1528Copyright (c) 2023 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:amp.cmp.org.pe:article/26312023-07-06T05:52:20Z
dc.title.none.fl_str_mv Hepatitis B and Delta in Peru: Current Status and Control
Situación y control de la hepatitis B y Delta en el Perú
title Hepatitis B and Delta in Peru: Current Status and Control
spellingShingle Hepatitis B and Delta in Peru: Current Status and Control
Cabezas Sánchez, Cabezas Sánchez
hepatitis B/epidemiología
transmisión
prevención & control
Hepatitis D/epidemiología
Perú
hepatitis B / epidemiology
transmission
prevention & control
hepatitis D / epidemiology
Peru
title_short Hepatitis B and Delta in Peru: Current Status and Control
title_full Hepatitis B and Delta in Peru: Current Status and Control
title_fullStr Hepatitis B and Delta in Peru: Current Status and Control
title_full_unstemmed Hepatitis B and Delta in Peru: Current Status and Control
title_sort Hepatitis B and Delta in Peru: Current Status and Control
dc.creator.none.fl_str_mv Cabezas Sánchez, Cabezas Sánchez
Cabezas Sánchez, César
author Cabezas Sánchez, Cabezas Sánchez
author_facet Cabezas Sánchez, Cabezas Sánchez
Cabezas Sánchez, César
author_role author
author2 Cabezas Sánchez, César
author2_role author
dc.subject.none.fl_str_mv hepatitis B/epidemiología
transmisión
prevención & control
Hepatitis D/epidemiología
Perú
hepatitis B / epidemiology
transmission
prevention & control
hepatitis D / epidemiology
Peru
topic hepatitis B/epidemiología
transmisión
prevención & control
Hepatitis D/epidemiología
Perú
hepatitis B / epidemiology
transmission
prevention & control
hepatitis D / epidemiology
Peru
description Hepatitis B virus is a highly infectious DNA virus, and the chronic carrier status may lead to cirrhosis and liver cancer. These conditions may supervene in a short time period if there is coexistence of both hepatitis B and D viruses, as it usually occurs in Peru. Our country has an intermediate endemicity, although there are areas with high, medium and low endemicity; however, migration is spreading these infections. It is important to point out that there is horizontal transmission in children from endemic areas and a low level of vertical transmission, which is an advantage in order to achieve early protection using the hepatitis B vaccine. This vaccine HBV is efficacious and safe, and vaccination is still one of the most cost-effective interventions. Pilot hepatitis B vaccination programs have been implemented in Peru, achieving a significant impact on the infection rates; so it is advisable to expand the target population, particularly teenagers and other risk groups, so that the time period to eliminate hepatitis B infection may be shortened, as well as its chronic sequels. There have been some advances in prevention, but we still have to take care of chronic carriers. Knowing that there are therapy strategies available for subjects positive and negative for HBeAg, it is advisable to propose therapy programs and to assess all interventions performed. These are the topics included in this review.
publishDate 2018
dc.date.none.fl_str_mv 2018-06-30
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/2631
url https://amp.cmp.org.pe/index.php/AMP/article/view/2631
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/2631/1528
dc.rights.none.fl_str_mv Copyright (c) 2023 ACTA MEDICA PERUANA
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 ACTA MEDICA PERUANA
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Colegio Médico del Perú
publisher.none.fl_str_mv Colegio Médico del Perú
dc.source.none.fl_str_mv ACTA MEDICA PERUANA; Vol. 25 No. 2 (2008); 96-112
ACTA MEDICA PERUANA; Vol. 25 Núm. 2 (2008); 96-112
1728-5917
1018-8800
reponame:Acta Médica Peruana
instname:Colegio Médico del Perú
instacron:CMP
instname_str Colegio Médico del Perú
instacron_str CMP
institution CMP
reponame_str Acta Médica Peruana
collection Acta Médica Peruana
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1842710633334702080
score 12.8608675
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).